Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 13/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042837 | 1.00 | HSD17B3 (0.48) | HSD17B3CYP11B1CYP11B2LDHAMKNK1 | |
| SCHEMBL5042619 | 0.90 | HSD17B3 (0.48) | HSD17B3CYP11B1CYP11B2LDHA | |
| SCHEMBL5042608 | 0.90 | HSD17B3 (0.48) | HSD17B3CYP11B1CYP11B2LDHA | |
| SCHEMBL5043107 | 0.89 | HSD17B3 (0.52) | HSD17B3 | |
| SCHEMBL5043105 | 0.89 | HSD17B3 (0.52) | HSD17B3 | |
| SCHEMBL5042551 | 0.82 | HSD17B3 (0.64) | HSD17B3 | |
| SCHEMBL5042553 | 0.82 | HSD17B3 (0.64) | HSD17B3 | |
| SCHEMBL5048370 | 0.80 | HSD17B3 (0.48) | HSD17B3CYP11B1CYP11B2LDHA | |
| SCHEMBL5048373 | 0.80 | HSD17B3 (0.48) | HSD17B3CYP11B1CYP11B2LDHA | |
| SCHEMBL4801032 | 0.79 | HSD17B3 (0.62) | HSD17B3CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1725565-A2 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | Bristol-Myers Squibb Company (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005084295-A2 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B1, HSD17B2 | HSD17B3 1/4885CYP11B1 24/4885CYP11B2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.